ACORI Call to Action Summit: Activating Equity in Community Oncology Research
The Association of Community Cancer Centers (ACCC) has established the ACCC Community Oncology Research Institute (ACORI) to build on its existing mission to close the gap in cancer research through optimal oncology partnerships. As part of this mission, ACCC hosted the ACORI Call to Action Summit, a two-day virtual event that explored practical solutions to strengthen and diversify oncology clinical trials in communities across the country...
View More
19th Annual New York Lung Cancers Symposium®
View More
Towards Personalized Treatment Approaches in Soft Tissue Sarcomas
View More
Show Me the Data: Bridging Clinical Gaps in Later Lines of Metastatic CRC… It’s Easy as VEGFR1, 2, 3!
View More
Practical Approaches to Modern Dry Eye Treatment and Management
February 20, 2025
Register Now!
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden
March 1, 2025
Register Now!
The Role of the Multidisciplinary Care Team in the Diagnosis and Management of Acute Hepatic Porphyria
March 14, 2025
Register Now!
Duration of Use Guidance Published for Systemic Corticosteroids in Atopic Dermatitis Treatment
The new position paper faults the absence of a clearly defined, evidence-based ceiling on duration of use for the persistent overuse of systemic corticosteroids for AD management.
Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension
Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.